Samuel Backenroth - Vascular Biogenics Chief Officer

Summary

VBLTDelisted Stock

USD 0.28 0.01 3.45%

Insider

Samuel Backenroth is Chief Officer of Vascular Biogenics

Age	39
Phone	972 8 993 5000
Web	https://www.vblrx.com

Samuel Backenroth Latest Insider Activity

Tracking and analyzing the buying and selling activities of Samuel Backenroth against Vascular Biogenics stock is an integral part of due diligence when investing in Vascular Biogenics. Samuel Backenroth insider activity provides valuable insight into whether Vascular Biogenics is net buyers or sellers over its current business cycle. Note, Vascular Biogenics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vascular Biogenics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Samuel Backenroth over a year ago

Exercise or conversion by Samuel Backenroth of 525000 shares of Vascular Biogenics subject to Rule 16b-3

Vascular Biogenics Management Efficiency

The company has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Vascular Biogenics to Peers

Vascular Biogenics currently holds 564 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Vascular Biogenics has a current ratio of 3.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vascular Biogenics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Chester III	Revelation Biosciences	45
	Richard MD	X4 Pharmaceuticals	62
	Andreas Bergthaler	Hookipa Pharma	N/A
	Eric MD	Acumen Pharmaceuticals	69
	PharmD Chiodin	Day One Biopharmaceuticals	N/A
	Renato Skerlj	X4 Pharmaceuticals	N/A
	Kerry MD	Terns Pharmaceuticals	N/A
	Annie Rasmussen	Allarity Therapeutics	67
	Keith MD	X4 Pharmaceuticals	54
	Pablo MD	ZyVersa Therapeutics	N/A
	Julie Bockenstette	Acumen Pharmaceuticals	N/A
	Murray MD	X4 Pharmaceuticals	63
	Arthur Taveras	X4 Pharmaceuticals	61
	Claus Pedersen	Allarity Therapeutics	52
	Steen Knudsen	Allarity Therapeutics	64
	Charles II	Day One Biopharmaceuticals	47
	Carol Odle	Revelation Biosciences	N/A
	James Foster	Virax Biolabs Group	40
	Mary DiBiase	X4 Pharmaceuticals	64
	James Rolke	Revelation Biosciences	56
	Alexandra MD	Avenue Therapeutics	58

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. Vascular Biogenics (VBLT) is traded on NASDAQ Exchange in USA and employs 7 people.

Management Performance

	Return On Equity	-0.6
	Return On Asset	-0.29

Vascular Biogenics Leadership Team

Elected by the shareholders, the Vascular Biogenics' board of directors comprises two types of representatives: Vascular Biogenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vascular. The board's role is to monitor Vascular Biogenics' management team and ensure that shareholders' interests are well served. Vascular Biogenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vascular Biogenics' outside directors are responsible for providing unbiased perspectives on the board's policies.

	Samuel Backenroth, Chief Officer
	Naamit Sher, VP of Devel. and Regulatory
	Yael Cohen, Vice President - Clinical Development
	Erez MBA, Sr Operations
	Eyal Breitbart, Vice President Research
	Deborah Scott, Managing Communications
	Pr MD, CEO Director
	Advocate Horn, G Counsel
	Tami MD, VP Devel

Vascular Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vascular Biogenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.6
	Return On Asset	-0.29
	Operating Margin	(33.89) %
	Current Valuation	(10.99 M)
	Shares Outstanding	77.64 M
	Shares Owned By Insiders	13.48 %
	Shares Owned By Institutions	14.00 %
	Number Of Shares Shorted	250.34 K
	Price To Earning	(9.32) X
	Price To Book	0.35 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Other Consideration for investing in Vascular Stock

If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.

	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC